Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia

Pick Disease of the Brain Clinical Trial

Official title:

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00674960
• Other study ID #: GAAD-FD-CTP1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: May 6, 2008
• Last updated: August 14, 2009
• Start date: May 2008
• Est. completion date: October 2009

Study information

• Verified date: August 2009
• Source: GAAD Medical Research Institute Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Pick's disease, also known as Pick disease,or FTD is a rare fronto-temporal neurodegenerative disease. This study will investigate the use of far infrared radiation for the control, management and treatment of Pick's disease.

Description:

This disorder causes progressive destruction of nerve cells in the brain and causes tau proteins to accumulate into the "Pick bodies" that are a defining characteristic of the disease. Tau proteins are microtubule-associated proteins that are abundant in neurons in the central nervous system and are less common elsewhere.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have FTD.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 0
• Est. completion date: October 2009
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• People with Pick's Disease

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Aphasia, Primary Progressive
• Frontotemporal Dementia
• Pick Disease of the Brain

Intervention

Radiation:
• Radiation: Far Infrared Radiation (5µm to 20µm wavelength)
Far Infrared Radiation (5µm to 20µm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Locations

Country	Name	City	State
Canada	The Centre for Incurable Diseases	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Therapy for FTD patients		1 year	No
Secondary	Rehabilitation of FTD Patients		1 Year	No